You cannot be forced to get the Covid vaccine. Here is the way out.
By Meryl Nass, MD | August 26, 2021
Let me show you how FDA, Pfizer and BioNTech colluded to fool everyone about the EUA status of the vaccine Americans will be offered. But close reading of their document gives you an escape route.
The “Fact Sheet for Recipients, “dated August 23, 2021, is approved by FDA and is on FDA’s website, and is signed by BioNTech and Pfizer.
Direct quotes from this easy to read 8 page document are below, and I suggest you print the document out, as it will help you avoid a vaccine mandate. Pay close attention. I added numbers to the most interesting excerpts.
After stating that you might receive the licensed vaccine or a vaccine under EUA in item 2, item 6 indicates that both the licensed vaccine AND the EUA vaccine are both under EUA. (This may be the way chosen to shield the licensed vaccine from liability.) Item 5 says that while under EUA, it is your choice whether or not to receive the vaccine.
Show this document to your college, your hospital, your boss. They cannot force you to receive either of these vaccines!
—————–
1. The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine under Emergency Use Authorization (EUA) have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series.[1]
2. You are being offered either COMIRNATY (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2.
3. The licensed vaccine has the same formulation as the EUA-authorized vaccine and the products can be used interchangeably to provide the vaccination series without presenting any safety or effectiveness concerns. The products are legally distinct with certain differences that do not impact safety or effectiveness.
4. WHAT IF I DECIDE NOT TO GET COMIRNATY (COVID-19 VACCINE, mRNA) OR THE PFIZER-BIONTECH COVID-19 VACCINE?
5. Under the EUA, it is your choice to receive or not receive the vaccine. Should you decide not to receive it, it will not change your standard medical care.
6. This EUA for the Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY will end when the Secretary of HHS determines that the circumstances justifying the EUA no longer exist or when there is a change in the approval status of the product such that an EUA is no longer needed.
Manufactured by Pfizer Inc., New York, NY 10017
Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany LAB-1451-7.2 Revised: 23 August 2021
American Medicine, American Malfeasance
By Dr. Gary Null and Richard Gale | Global Research | June 26, 2021
An issue that is rarely discussed or given serious attention is the over-specialization in healthcare. Modern medicine’s approach to identify and treat illnesses and tackle the reduction of infections has in many instances ceased to be multidisciplinary. Medicine has also become increasingly compartmentalized and confined to a rigid materialistic belief system that has now established its own set of standards, criteria and values that are often contrary to gold-standard scientific protocols. The consequence is that its narrow single-mindedness has insulated modern medicine from objective criticism and preserved its internal flaws, errors and fabrications, which have contributed to the unnecessary injury and death of countless patients.
US healthcare spending reached $3.8 trillion in 2019. Due to the Covid pandemic, expenditures for 2020 will be astronomically higher. One might expect that with the world’s most expensive healthcare system, the US would equally have the best evidence-based practices to keep its citizens healthy. By now we should be proficiently expert at preventing and reversing disease, while making minimal errors resulting in injury or death. However, the exact opposite is the case. Instead of minimizing disease-causing factors, American medicine causes more illness through misguided diagnostic testing, overuse of medical and surgical procedures, and over prescribing pharmaceutical drugs. The fundamental reason for this catastrophe is that today’s healthcare establishment, and corporate science in general, over relies on profit-generating motives.
Dr. Peter Gotzsche is arguably recognized as one of the world’s foremost experts in evaluating evidence-based medicine (EBM). As the co-founder of EBM’s preeminent flagship organization – the Cochrane Collaboration — to review and analyze peer-reviewed clinical research, he is intimately knowledgeable about the widespread corruption permeating the pharmaceutical industry and medical journals. In his book Deadly Medicines and Organized Crime, he writes,
“The reason why we take so many drugs is that drug companies do not sell drugs. They sell lies about drugs… The patients do not realize that although their doctors know a lot about diseases, human physiology and psychology, they know very little about the drugs that have been concocted and dressed up by the drug industry.”
After we take a fair and objective look at American medicine during the past five decades, especially at the statistics of iatrogenic fatalities, or deaths caused by prescribed medications and medical error, our healthcare establishment is found to be anything but benign. Despite its many noteworthy discoveries and merits, a substantial amount of recommended medical practice has failed patients. “If the medical system were a bank,” writes Dr. Stephen Persell at Northwestern University’s School of Medicine, “you wouldn’t deposit your money here, because there would be an error every one-in-two to one-in-three times you made a transaction.” Dr. Persell is referring to the rates of preventable medical errors causing patients serious injury and now the third leading cause of death.
There is excellent evidence to support the argument that iatrogenic deaths have passed cancer fatalities and are now challenging heart disease for the number one spot. A 2008 study found as many as half of adverse events reported by patients were not recorded in their hospital charts. As of 2017, investigations continue to find that less than 10% of medical errors are reported. Reported adverse effects vary depending on the specialty and frequently go unnoticed or are improperly evaluated. An additional study found that almost two thirds of cardiologists had refused to report a serious error they had direct personal knowledge of to an authority.
As one example, heart disease is America’s leading cause of fatality, accounting for 665,000 deaths annually. The CDC, which consistently undermines health threats if it means positioning itself in opposition to private commercial interests, estimates that 34 percent of cardiovascular fatalities are premature and preventable. In contrast, the American Heart Association claims 80 percent are preventable. What are the heads of our federal health agencies doing to advocate on the side of prevention? Little to nothing.
There is no realistic and science-based national policy in place to lessen cardiovascular, cancer and diabetic death rates. Since the most viable and effective means to prevent these diseases are natural and within every person’s means, it is not financially lucrative to divert federal funding away from pharmaceutical treatments and surgical procedures. The CDC and FDA are largely dependent upon monetary income received from the drug and medical device industries.
Earlier we reported about the systemic corruption and fraud that has plagued the CDC and FDA for decades. It would be far cheaper to completely empty, dismantle, fumigate and rebuild the agencies anew rather than continue exerting pressure for reforms, which have only perpetuated a killing spree by protecting life-threatening drugs, vaccines and unnecessary medical procedures. Dr. Gotzsche notes, the same is true for private drug companies. Despite the numerous lawsuits drug companies have lost in federal courts, nothing has fundamentally changed in order to deter them from illegal activities to increase profits. In fact, the cost of paying out settlements and settling lawsuits is factored into the expense of doing business.
A decade ago, we teamed up with three board-certified physicians to undertake the task to review the peer-reviewed literature in order to recalculate the statistics from many branches of medicine in order to arrive at a more realistic casualty rate due to medical error. We began with a basic question. Do the current standards of American medical practice and its supporting science prove that the recommended therapies and healthcare protocols – whether drugs, surgery, diagnostic methods, medical devices, etc – are actually effective? And if so, at what cost to the patients’ health and well-being?
Our results and final conclusions were startling and culminated in the release of a widely read and referenced book, Death by Medicine. We made every effort to avoid editorial commentary to our findings. We decided to only report the statistics and facts with our calculations. The fact that our data placed iatrogenic error as the number one cause of death in America was alone sufficient. What was novel in our analysis was that we included preventable deaths, such as certain infections and severe nutrient deficiency, which could have been easily corrected by clinicians and medical personnel if viable prevention programs had been part of our healthcare system. After publication the book was sent to hundreds of journalists, federal officials and non-profit medical organizations. It was completely ignored by the orthodoxy; however, it became increasingly popular among alternative and complementary medical physicians who were already fully aware of the structural dangers to public health within conventional medical care.
Revisiting American medicine’s legacy of iatrogenic deaths is now more crucial than ever because the same behaviors that have contributed to the nation’s leading cause of death are being repeated during the Covid-19 pandemic. The government and federal health officials are in reprehensible denial of inexpensive and highly effective drugs, such as Ivermectin and hydroxychloroquine, to treat early and middle stage SARS-2 infections. Cases of Covid infections and deaths have been grossly exaggerated. And now we are realizing that the efficacy and safety profiles of the vaccines are orchestrated scams. As a result, the entire institutional edifice to vaccinate the global population is destined to become the greatest scandal of the 21st century.
Unfortunately, nobody can acquire accurate statistics for Covid-19 vaccine associated injuries and deaths from the CDC’s Vaccine Adverse Events Reporting System (VAERS). Careful weekly monitoring of VAERS’ adverse event updates convince us that the entire system is criminally rigged. CDC officials overseeing the database are undoubtedly fudging numbers after ratio of adverse events, including deaths, per number of doses administered are compared to the more robust and accurate EudraVigilance database in the European Union and the less reliable Yellow Card System in the UK.
As of June 17, VAERS was reporting 329,021 injuries and 5,888 deaths due to the Covid vaccines. The database’s most recent update is reporting an additional 26,541 injuries but 1,972 less deaths. How can this sudden disappearance of almost 2,000 deaths be accounted for? The mysterious loss of fatality entries occurred during the same week as a CDC working group of outside medical professionals was reviewing an association between the mRNA vaccines and the rising number of reported cases of cardiac inflammation or myocarditis. The group concluded that there is indeed “a likely association.” The occasion of deleted deaths in VAERS is also on the heels of the Israeli Shamir Medical Center report that Pfizer’s vaccine is linked with occurrences of thrombotic thrombocytopenic purpura, an autoimmune disorder associated with a rare form of blood clotting. However, despite weekly local news stories around the nation about youth as young as 19 years of age dying of vaccine complications shortly after receipt of an mRNA vaccine, the CDC is claiming that all 1,200 persons, between 16-24 years of age, recovered and no deaths were reported. Does this account for the likely scrubbing of entries in VAERS?
But it is much worse. We only need to look at the European Union’s statistics for adverse Covid-19 vaccine events and compare that with VAERS and the CDC’s recent conclusion to realize there is a massive cover-up in our government’s efforts to sanitize the safety record of Covid vaccines. As of this week the EudraVigilance system is reporting over 1.5 million injuries and 15,472 deaths. Within those figures, 28,583 injuries and 1,862 deaths are from cardiac complications such as myocarditis.
Second, the EU and US have administered approximately the same number of Covid vaccine doses, roughly 409 million and 379 million respectively. Therefore we should expect to find a similar dose-to-injury ratio. Again we discover the CDC gaming the nation’s reporting system to lessen the perception of lethal risks. Based upon the EU ratio we can conservatively estimate that a minimum of 14,300 Americans have been killed by the vaccines so far. If we go back a week before the CDC scrubbed entries in VAERS, it would be over 17,000 Covid vaccine deaths. The actual number of Americans suffering adverse reactions would be 1.4 million.
In other words the EU is reporting 4 times more vaccine injuries and deaths than American health officials. In both the US and EU, Pfizer’s mRNA vaccine accounts for the majority of these casualties. Unless the Covid-19 vaccines engineer a personal vendetta against people holding EU passports, these numbers don’t add up.
Before the arrival of the Covid vaccines, Merck’s anti-inflammatory drug Vioxx was widely regarded as the single largest pharmaceutical catastrophe in American medical history. The drug should never have been approved and licensed in the first place; and, Merck knew beforehand that the drug would be lethal and concealed that documentation from FDA regulators. Vioxx was on the market for five years before being withdrawn. At the time of the federal class action lawsuit against Merck, FDA epidemiologist Dr. David Graham estimated the drug had killed 60,000 patients due to heart attacks and strokes. Since the majority of deaths were among elderly patients, a later report by the American Conservative predicted that upwards to half a million patients may have died from the drug over the course of a longer period. Yet during those years Merck was cashing in $2 billion annually from Vioxx sales, earning over double its eventual $4.8 billion fine after being found guilty.
To put this into a broader perspective, the Covid vaccines have only been distributed for six months and have now contributed to a realistic 17,000 deaths or upwards towards 30,000 this year alone. Since the vaccines’ immunity quickly wanes and it seems certain they provide little protection against new SARS-2 strains, health officials are already recommending regular booster shots. Similar to a prescription medication, those who buy into the vaccine propaganda hype are in principle relying upon these vaccines for life or until such time the virus resides into just a seasonal nuisance. Consequently iatrogenic vaccine injuries and deaths may likely continue at current rates during forthcoming years. The Covid-19 vaccines are on track to outpace the conservative number of Vioxx deaths over three-fold and even modern medicine’s most deadly drugCerivastatin, manufactured by Bayer in the late 1990s and responsible for over 100,000 deaths during the four-year period it was on the market. In short time, Covid vaccines will be the deadliest drug to have emerged from Big Pharma.
A study published in the Journal of Patient Safety estimated that 400,000 unnecessary and preventable deaths occur annually in American hospitals alone. At that rate, it is not surprising that the large majority of deaths ruled as SARS-2 infections happened in hospitals. If our federal health officials had been competent, and less compromised by the demands and influence of drug makers, most of these fatalities likely would never have occurred.
It has been estimated that US taxpayers have paid out $39 billion for Covid-19 vaccine development, funding and towards nationalized response measures. Most of this has been horribly wasted after we consider other options on hand to curb the pandemic but were categorically ignored. “In the case of vaccines in general,” the journal Health Affairs observed,
“the government often plays an outsized role, but in the era of Covid-19 the government’s role was even more central than usual. The government essentially removed the bulk of traditional industry risks related to vaccine development: a) scientific failures, b) failures to demonstrate safety and efficacy, c) manufacturing risks, and d) market risks related to low demand.”
While this may shock and disturb a rational person, Health Affairs – a thoroughly orthodox medical publication – applauds the government’s negligent measures as “money well spent.”
For this reason it is crucial to understand the terrible decisions made during the Covid pandemic in the context of modern medicine’s past crimes and preventable failures. In the coming months Anthony Fauci’s reputation will become further tainted. We might predict he will resign as more evidence of incompetence emerges, and, in our opinion, perhaps criminal negligence in his handling of the pandemic and efforts to whitewash the US’s role in supporting gain of function research leading to the genetic engineering of the SARS-2 virus. Fortunately, unlike past scandals when misguided medical decisions were responsible for thousands of unnecessary disabilities and deaths, numerous doctors and scientists worldwide are raising their voices to condemn the lethal policies of the CDC, NIAID, British Health Ministry and the World Health Organization.
So what can we reasonably surmise at this point? At one time most Americans trusted science, medicine and our healthcare system without question or criticism. However, today we observe systemic corruption and gross conflicts of interest across the same federal health agencies that have also contributed to untold medical errors and deaths prior to SARS-2 arrival. They have weaponized pharmaceutical science and a supplicant braying media supports this perversion of medical facts. Now the drug-happy media is attacking the truth-tellers, the physicians, professors and accomplished journalists who are risking their careers and reputations to bring forth the fallacies in the pandemic narrative. This is one battle that the silent majority can find its voice and courage to step forth and support.
Richard Gale and Gary Null PhD direct Progressive Radio Network.
The anti-Covid pill Big Pharma doesn’t want you to have
By John Hollaway | The Conservative Woman | June 22, 2021
From Wikipedia: ‘During the 2020 COVID-19 pandemic, misinformation was widely spread claiming that ivermectin was beneficial for treating and preventing COVID-19. Such claims are not backed by good evidence.’
WHEN encountering an inexplicable anomaly in human behaviour, common rules of thumb can often give an insight. Oddly, though, these differ from country to country. For Americans it is ‘follow the money’. For Italians it is ‘cui bono?’ – who benefits? The nearest French rule is perhaps ‘cherchez la femme’.
Sometimes none of these help. Sometimes a perverse piece of human nature cannot be explained in terms of money, perquisites or feminine influence. The ivermectin mystery is one such.
Ivermectin is a generic prescription drug, discovered in 1975, developed by Merck and released in 1981. It is used to treat many types of parasite infestations in humans and animals. The researchers who created it were awarded the Nobel Prize for medicine in 2015. It is on the World Health Organisation’s List of Essential Medicines and is approved by the Federal Drug Administration (FDA) as an antiparasitic agent.
It can have very rare serious side effects. By 2020 four billion doses had been administered and 16 deaths are believed to have occurred as a consequence, or one in 250million doses. Although the figures are not directly comparable, the annual increased risk of death for a middle-aged man taking a standard (325 mg) aspirin every day to prevent heart disease and stroke is about one in ten thousand. This is about as risky as driving a car.
Ivermectin is therefore a very safe drug. However, the drug oversight establishment does not think so.
On March 22 this year the European Medicines Agency issued this statement:
‘EMA has reviewed the latest evidence on the use of ivermectin for the prevention and treatment of COVID-19 and concluded that the available data do not support its use for COVID-19 outside well-designed clinical trials.
‘In the EU, ivermectin tablets are approved for treating some parasitic worm infestations while ivermectin skin preparations are approved for treating skin conditions such as rosacea. Ivermectin is also authorised for veterinary use for a wide range of animal species for internal and external parasites.
‘Ivermectin medicines are not authorised for use in COVID-19 in the EU, and EMA has not received any application for such use.’
On May 3 the US Food and Drug Administration (FDA) issued this warning under the heading ‘Why You Should Not Use Ivermectin to Treat or Prevent COVID-19’:
‘There seems to be a growing interest in a drug called ivermectin to treat humans with COVID-19. Ivermectin is often used in the U.S. to treat or prevent parasites in animals. The FDA has received multiple reports of patients who have required medical support and beenhospitalized after self-medicating with ivermectin intended for horses.
‘FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans. Ivermectin tablets are approved at very specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an anti-viral (a drug for treating viruses).
‘The FDA has not reviewed data to support use of ivermectin in COVID-19 patients to treat or to prevent COVID-19; however, some initial research is underway. Taking a drug for an unapproved use can be very dangerous. This is true of ivermectin, too.’
The lack of official support for trials of the efficacy of ivermectin has meant that the typical number of subjects being tested (the ‘cohort’) is fairly small, usually about a hundred. To overcome this a meta-analysis can be undertaken, when the results of many trials are combined and assessed to determine if a trend can be seen. This has been done, most notably by @CovidAnalysis. A paper most recently updated yesterday surveyed 60 properly conducted studies, most with double-blind testing against placebos, with neither the participants nor the researcher knowing who had been given the drug until the trial was over. This report is a preprint, so it has not been peer-reviewed, but the results are conclusive: 93 per cent of the studies show a positive outcome from the administration of ivermectin, with deaths reduced by over 80 per cent.
So why have what might be called ‘Drug Central’ refused to acknowledge this mammoth body of evidence arising from without their bailiwicks? Perhaps because of human nature again. Here they are obeying another rule of thumb commonly seen when institutions encounter new external factors – ‘not invented here’. Perhaps this business school aphorism is also appropriate: ‘Hell hath no fury like a head-office scorned’.
In any event the virucidal properties of ivermectin and its safety have now been established beyond doubt, and we can expect it to be valuable in this role from henceforth. But unfortunately not, perhaps, against Covid-19.
FDA gives Emergent BioSolutions a consolation prize: it must throw out 60 million vaccine doses but can sell 10 million, which will be labeled as failing GMP standards
By Meryl Nass, MD | June 11, 2021
Now this is a really odd FDA decision. FDA is acknowledging that the 10 million doses it is authorizing is adulterated. But adulterated doses can’t be sold. But EUA products don’t generally get sold, except to the US government. I am scratching my head. I thought all these doses were already bought and paid for, by the taxpayer.
And there seem to be another 100 million doses about which FDA has not made up its mind.
This echoes FDA’s decision last week to license a very expensive but ineffective Alzheimer’s drug, after its advisory committee unanimously voted against it.
We always knew FDA was a political organization. But now, without Biden having appointed anyone to its helm, its decisions are wilder than ever.
From the NY Times today:
WASHINGTON — Federal regulators have told Johnson & Johnson that about 60 million doses of its coronavirus vaccine produced at a troubled Baltimore factory cannot be used because of possible contamination, according to people familiar with the situation.
The Food and Drug Administration plans to allow about 10 million doses to be distributed in the United States or sent to other countries, but with a warning that regulators cannot guarantee that Emergent BioSolutions, the company that operates the plant, followed good manufacturing practices.
The agency has not yet decided whether Emergent can reopen the factory, which has been closed for two months because of regulatory concerns, the people said.
The Johnson & Johnson doses administered in the United States so far were manufactured at the firm’s plant in the Netherlands, not by Emergent. For weeks the F.D.A. has been trying to figure out what to do about at least 170 million doses of vaccine that were left in limbo after the discovery of a major production mishap involving two vaccines manufactured at the Baltimore factory.
THIRD member of FDA advisory body resigns, calls Alzheimer’s drug approval ‘worst in recent US history’
RT | June 10, 2021
Three scientists from a FDA advisory committee have resigned after the US food and drug regulator rammed through the approval of a controversial drug to treat Alzheimer’s disease in the face of near-unanimous opposition.
Ten out of 11 members of the Peripheral and Central Nervous System Advisory Committee voted against approving the drug aducanumab, with one voting “uncertain,” during the hearings in November 2020. On Monday, the FDA granted it accelerated approval anyway.
“This week, the aducanumab decision by FDA administrators was probably the worst drug approval decision in recent US history,” wrote Aaron Kesselheim of Harvard and the Brigham and Women’s Hospital in Boston, Massachusetts – who became the third member of the committee to resign in protest this week.
The agency switched to accelerated approval “at the last minute,” based on the “debatable premise” that the drug’s effect was likely to help patients, but “this pivotal question was not discussed at the Advisory Committee meeting, and its premise was specifically excluded from discussion,” Kesselheim wrote. Furthermore, some of the questions asked of the committee were “worded in a way that seemed slanted to yield responses that would favor the drug’s approval.”
Kesselheim, who has served on the committee since 2015, said it was “clear to me that FDA is not presently capable of adequately integrating the Committee’s scientific recommendations into its approval decisions.”
Two neurologists serving on the committee – David Knopman of the Mayo Clinic in Minnesota and Joel Perlmutter of Washington University in St. Louis, Missouri – resigned on Wednesday.
Developed by the Cambridge, Massachusetts-based Biogen and Japan’s Eisai, aducanumab – also known by the trade name Aduhelm – was touted as the first treatment that directly targets the cause of Alzheimer’s disease, instead of merely helping to ease its symptoms. Biogen’s stock surged at the news that the intravenous treatment – the cost of which is estimated at $56,000 a year – had been greenlit by regulators.
Aduhelm is a monoclonal antibody designed to remove a substance called amyloid from the brain of Alzheimer’s patients. Doctors are not in agreement whether this is the cause or the symptom of the disease that presently afflicts an estimated six million Americans. Clinical trials were halted in 2019 after the drug was not shown to be effective, but Biogen “re-analyzed” the data and told the FDA that some patients who received higher doses had shown a slower rate of decline than others.
The FDA then argued that the drug “is reasonably likely to predict a clinical benefit to patients,” even if it did not show clear clinical benefits in slowing down the progression of Alzheimer’s.
Aduhelm was the final straw for Kesselheim, whose letter also cited an earlier incident with the drug called eteplirsen, approved in 2016 for treatment of Duchenne muscular dystrophy against the advisory recommendations.
“For both eteplirsen and aducanumab, the decisions by FDA administrators to ignore the Advisory Committee’s clear recommendations led to their approval of two highly problematic drugs that offered little evidence that they would meaningfully benefit patients suffering from these devastating conditions,” he wrote, adding that the dual debacles “demonstrate that the agency needs to reassess its decision-making processes.”
FDA Approves Non-effective New Alzheimer’s Drug Despite Their Own Doctors Recommending AGAINST It

By Brian Shilhavy | Health Impact News | June 9, 2021
Big Pharma has been trying to create a blockbuster drug for the very lucrative Alzheimer’s Disease for more than a decade.
But they have repeatedly failed, mainly because they start with the wrong presuppositions on the cause of Alzheimer’s, basing it on “genetics” instead of environmental causes.
The over 55 age population has always been a cash cow for Big Pharma, as the most profitable drug of all time was Pfizer’s Lipitor, a statin drug that artificially lowers one’s cholesterol.
Prior to its patent expiring at the end of 2011, no other drug in human history had racked up more sales than this one single drug, as their advertising campaign against cholesterol resulted in doctors placing nearly one out of every four people over the age of 55 on statin drugs to lower their cholesterol.
But 25% of our body’s cholesterol resides in our brains, so there have been honest researchers over the years, such as Dr. Stephanie Seneff at MIT, who have linked low cholesterol to a rise in Alzheimer’s Disease. See:
The Clue to Why Low Fat Diet and Statins may Cause Alzheimer’s
And so it is no surprise that coconut oil, demonized by Big Pharma, the USDA, the FDA and just about every other regulatory agency in the U.S. since the 1970s, can provide dramatic improvement to Alzheimer’s Disease and other forms of dementia, often with dramatic results.
See our body of research provided over the years on coconut oil, along with amazingly dramatic testimonials for curing Alzheimer’s here.
We have covered all the previous failures of Big Pharma to produce a drug to treat Alzheimer’s over the years, but just this week the FDA finally approved a drug for the treatment Alzheimer’s Disease.
But as reporter Andrew Joseph of Stat News writes, the FDA did so in spite of the fact that their own 11 doctor expert panel had 10 of those doctors state that “there was not enough evidence to show it could slow cognitive decline,” and the 11th doctor voted “uncertain.”
And now one of those doctors, Neurologist Joel Perlmutter of Washington University in St. Louis, has resigned. … continue
Pharma Controlled FDA Approves Inadequately Tested Alzheimer’s Drug
By Stephen Lendman | June 9, 2021
According to the Alzheimer’s Association, around 6 million Americans suffer from the degenerative disease.
The number is projected to more than double by 2050.
One in three US seniors dies from Alzheimer’s disease or dementia — more than breast and prostate cancer combined.
In 2021, treating Alzheimer’s and dementia patients cost an estimated $355 billion.
By 2050, the cost is expected to be about $1.1 trillion.
Over 11 million American families have one or more members afflicted by these diseases.
From 2000 – 2019, US deaths from heart disease declined by 7.3% while individuals in the country dying from Alzheimer’s disease rose by 145%.
Professor of Medicine, medical ethics and neurology Dr. Jason Karlawish is board certified to practice geriatric medicine.
Among his extensive credentials, he heads the University of Pennsylvania’s Neurodegenerative Disease Ethics and Policy Program, is associate director of the Clinical Core and co-associate director of the Alzheimer’s Disease Core Center, as well as co-director of the Penn Memory Center.
He’s involved with the Healthy Brain Research Network.
It’s dedicated to surveillance, education, awareness, empowerment and promotion of brain health.
He heads makingsenseofalzheimers.org at the University of Pennsylvania’s Neurodegenerative Disease Ethics and Policy Program.
As part of his research on neuroethics and policy, he investigated issues in dementia drug development, informed consent, quality of life, and treatment decision-making.
On May 30 — days before the FDA’s premature approval of Biogen’s experimental, inadequately tested aducanumab Alzheimer’s drug — Karlawish minced no words saying the following:
If approved, “I won’t prescribe it,” adding:
When asked if any new safe and effective drugs exist to treat Alzheimer’s disease, he unequivocally said, “No.”
He’s been saying the same thing “for the past 18 years,” he explained.
Drugs he prescribes to ease cognitive problems “are only moderately effective.”
No magic bullet otherwise exists.
No drugs slow cognitive impairment to let affected individuals maintain control over their lives.
He and colleagues involved in treating Alzheimer’s patients won’t prescribe aducanumab because “Biogen hasn’t made a convincing case for it,” he explained, adding:
“The consequences of FDA approval are as disturbing as they are vast.”
Millions of “Americans could be prescribed aducanumab, at an estimated cost that ranges from $20,000 to $50,000 per person per year.”
“Biogen claims the benefits of slowing declines in cognition and day-to-day function are worth this price.”
Karlawish disagrees, saying Biogen data are “murky.”
“(T)he drug’s benefits are ambiguous at best and not worth this cost.”
“Putting it on the market will stress Medicare’s resources.”
Dubious benefits will force families of Alzheimer’s patients to decide if the high cost is worth the risks posed by the drug.
One risk “is small bleeds in the brain, a risk that is heightened in those with the APOE4 gene, a gene associated with late-onset Alzheimer’s disease,” Karlawish explained.
“Aducanumab is not the drug to launch a new era of Alzheimer’s treatment.”
“It hasn’t been properly studied…so the FDA has incomplete data to form a judgment.”
What’s going on is “good for business but bad for science and patient care.”
According to investors.com, after aducanumab failed two final-phase studies in March 2019, Biogen’s stock lost a third of its value.
After a phase-three test suggested promise — despite 10 members of an FDA advisory committee recommending against its approval — Biogen’s stock rose over 30%.
According to biotech company Cassava Sciences’ CEO Remi Barbier, the anti-amyloid approach used by Biogen “failed repeatedly…for the past 25 – 30 years, adding:
“Normally, when an approach fails, sometimes you try again.”
“Certainly, three strikes and you’re out.”
“It’s been 20 strikes and they’re still batting.”
Biogen is a troubled company.
According to investors.com, generics are eating into sales of its biggest moneymaker, the multiple sclerosis treatment Tecfidera.”
“In the first quarter, Tecfidera sales plunged 56%.”
In partnership with Ionis Pharmaceuticals, sales of Biogen’s spinal muscular atrophy drug Spinraza fell about 8%.
Is FDA approval of aducanumab more about preventing Biogen’s bankruptcy than treating Alzheimer’s patients safely and effectively?
Before the drug’s approval, macreoaxis rated possible Biogen bankruptcy at 28.56% because of its troubled financial situation.
In Phase 2 clinical trials, the FDA let Biogen “skip a crucial step in drug development…to assure that the final phase of testing (Phase 3) will make a convincing case that the drug should be marketed to providers and patients,” Karlawish explained, adding:
“Biogen’s application for approval divided the FDA.”
Its advisory committee sided with the yeas over the neas even though the latter case was much more convincing.
Company data on aducanumab are “incomplete and contradictory,” said Karlawis.
“Skipping a key phase of research” was a business, not a science-based, decision.
Families with an Alzheimer’s disease member are grasping at whatever may offer hope.
The verdict on aducanumab won’t be known unless “Biogen invests the time and money needed to run well-designed trials and complete them,” Karlawis stressed.
Given premature FDA approval, they’re highly unlikely to be conducted.
Aducanumab users will be playing Russian roulette with their health by volunteering as virtual guinea pigs with an inadequately developed drug that may make a bad situation worse.
Illegitimate rules remove parental consent for Covid vaccines
The Rule of Law is being dismantled and our children are the prey
By Meryl Nass, MD | May 31, 2021
Continuing from the last post: the US had very high rates of Covid compared to many countries, and right now that seems to have been a good thing… since places like Australia and New Zealand seem to want to be able to impose lockdowns for the forseeable future as they pursue the impossible goal of zero Covid. Impossible because you are not going to get everyone on the planet to accept a shot, and then vaccinate the wild animals and pets who are also susceptible. We have basically reached herd immunity with a combination of vaccine and natural immunity. Since only 40% of the US population is fully vaccinated, according to the NYT, there has undoubtedly been a considerable amount of natural immunity that has accrued.
Why aren’t the media celebrating? Apparently the powers that be who have made so many disastrous decisions regarding pandemic management don’t want us to know this. Yet. Thus their huge hurry to vaccinate despite the law, despite the still experimental nature of the vaccine products:
* The colleges demanding vaccinations
* The employers firing the unvaccinated
* The authorization for 12-15 year olds
* The million dollar lotteries for vaccinees, and other excesses to coerce vaccinations
But now the ante has been upped even higher. While many laws have been disregarded during the pandemic emergency, under the rubric of an emergency, two things I learned today are the worst.
Children aged 12-15 are being invited to vaccine clinics without parental permission, in the cities of San Francisco and Philadelphia, and others, based on emergency edicts in local jurisdictions, coupled with a Declaration by Alex Azar in March 2020 broadening the liability waiver umbrella for “covered countermeasures” during a pandemic to virtually anyone who has anything to do with a vaccine program. This could be interpreted as covering anyone who chooses to mandate the vaccine, even while experimental. In other words, even though you are not permitted to mandate an experimental product, Alex Azar said he would not allow you to be punished if you did so.
There do exist real laws, which preceded the pandemic, that protect children as a special class from both being used as experimental subjects (which legally under EUA this is) and protect them by requiring parental consent for procedures, unless they are emancipated minors.
Unless these laws were revoked while I blinked, they still exist and as federal laws should supercede anything imposed by a lesser jurisdiction.
Let’s see what happens. This is “hot” news and I don’t have time to put in the links, but this is true.
Finally, the FDA has announced its vaccine advisory committee will meet on June 10 to advise (aka bless) FDA on authorization and/or licensure for pediatric Covid vaccines. Not to put too fine a point on it, it is possible the FDA will authorize Covid vaccines for younger children, or even license them, starting June 11.
Meanwhile, Israeli media have claimed that one in 3 to 6 thousand vaccinees (I think in the 15-30 age group) develops myocarditis. I am trying to get the official report on this.
It is likely the FDA is trying to forestall any more bad news, which is why it is moving so rapidly. Furthermore, the FDA has warned us that it may not be able to provide any background documents prior to the June 10 meeting. That means the public and the advisors may be entirely in the dark as the advisors vote to provide their approval for whatever the FDA has up its sleeve.
Meanwhile, the Indian Bar Association has served legal notice for suppression of ivermectin against the WHO Chief Scientist, who is a famous Indian who headed up the Indian Council of Medical Research before transferring to the WHO.





